Pasquale CAPONNETTO

Assistant Professor of CLINICAL PSYCHOLOGY [M-PSI/08]

Degree in Psychology (clinical and community) in 2001 at La Sapienza University of Rome. PhD in Health Science at the Faculty of Health Sciences University of Stirling (UK) with a thesis on anti-smoking treatments for patients with schizophrenic spectrum disorders conducted between the University of Catania, University of Stirling (UK), King’s College London (UK), City University of New York (USA), Cornell University New York (USA). Specialization in Relational Psychotherapy at the Italian Institute of Relational Psychotherapy, Rome (recognized by the MIUR). Master’s degree in criminological and penitentiary sciences, University of Catania. Training in Ericksonian psychotherapy (foundamental level) at Milton H. Erickson Foundation, USA. He has carried out clinical and research activities at rehabilitation clinics affiliated with the NHS for the treatment and research of serious mental illness, clinical and research activities at the NHS for victims of domestic violence, family counseling, Psychological support during the COVID pandemic and services for the treatment and prevention of addictions and eating disorders in adolescents and adults. He has developed a line of research on harm reduction therapies in the general population and in fragile patients such as those suffering from severe psychopathology, chronic and young diseases and a line of research focused on Cyber Health Clinical Psychology. The same studies led him to be external auditor for Cancer Research UK and editor in chief for international journals such as Health Psychology Research and IJERPH. At the University of Catania from 2009 to 2017 as research fellow to coordinate the activities of an integrated psychobehavioural research project dedicated to smokers with diabetes. Since then he has continuously carried out his research at the University of Catania studying the psychological and psychopathological components emerging in the different research projects managed by the Center of Excellence for the acceleration of Harm Reduction (Coehar). Since 2022 he has held the position of RTD B) at the aforementioned University. He has published 133 scientific papers in peer-reviewed journals and received over 3500 citations. 2023 Visiting Researcher  Geisel School of Medicine at Dartmouth College, Center for Collaborative Mental Health Research at Dartmouth-Hitchcock (USA)

VIEW THE PUBLICATIONS
N.B. the number of publications can affect the loading time of the information
VIEW THE COURSES FROM THE A.Y. 2022/2023 TO THE PRESENT

Academic Year 2021/2022


Academic Year 2020/2021


Academic Year 2019/2020


Academic Year 2018/2019


Academic Year 2017/2018


Academic Year 2016/2017
  • DEPARTMENT OF BIOMEDICAL AND BIOTECHNOLOGICAL SCIENCES
    Bachelor's Degree in Orthoptic and ophtalmologic assistance - 2nd Year
    PSICOLOGIA CLINICA E IPOVISIONE GENERALE

  • DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES AND ADVANCED TECHNOLOGIES
    Master's Degree in Health Professions of Rehabilitation Sciences - 1st Year
    C.I. MEDICINA E CHIRURGIA II

  • DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES AND ADVANCED TECHNOLOGIES
    Bachelor's Degree in Speech and Language Therapy - 3rd Year
    CLINICAL PSYCHOLOGY



Academic Year 2015/2016
  • DEPARTMENT OF BIOMEDICAL AND BIOTECHNOLOGICAL SCIENCES
    Bachelor's Degree in Orthoptic and ophtalmologic assistance - 2nd Year
    PSICOLOGIA CLINICA E IPOVISIONE GENERALE

  • DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES AND ADVANCED TECHNOLOGIES
    Bachelor's Degree in Audioprothesic Techniques - 1st Year
    AUDIOPROTESI

  • DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES AND ADVANCED TECHNOLOGIES
    Master's Degree in Health Professions of Rehabilitation Sciences - 1st Year
    C.I. MEDICINA E CHIRURGIA II

  • DEPARTMENT OF MEDICAL AND SURGICAL SCIENCES AND ADVANCED TECHNOLOGIES
    Bachelor's Degree in Speech and Language Therapy - 3rd Year
    CLINICAL PSYCHOLOGY
  1. My research has focused on tobacco addiction among adolescent and adults and worked on studies of mental illnesses, asthma, diabetes and electronic cigarette.. This work involved clinical practice and observational studies as well the use of clinical trials. I’m currently working on electronic cigarettes, tobacco harm reduction, cognitive functioning and smoking or vaping, smoking and diabetes and consumer behavior.

 

  1. Polosa R, Caponnetto P (2013). Time for evidence-based e-cigarette regulation. Lancet Oncol. 2013 dec;14(13):e582-3
  2. Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R (2013). Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. g.     Int J Environ Res Public Health 10(2):446-461.
  3. Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, Russo C.Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014 May 8;11(5):4965-77
  4. Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C (2014). Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health.  Nov 8;14:1159.

 

 

Complete List of Published Work in MyBibliography:  

https://www.ncbi.nlm.nih.gov/pubmed/?term=caponnetto+p

 

 

D. Research Support

Ongoing Research Support

 

1 NCT01387425

Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE), Caponnetto P., Co-Investigator

This protocol is intended to provide information regarding the efficacy and safety of the nicotine partial agonist varenicline tartrate, at a dose of 1 mg twice daily, for smoking cessation in diabetic subjects who smoke.

 

2. NCT01979796

Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning (SCARIS). Caponnetto P., Principal Investigator

a randomized controlled trial investigating the efficacy and safety of electronic cigarette. The trial will take the form of a prospective 12-month randomized clinical study to evaluate smoking reduction, smoking abstinence and adverse events in schizophrenic smokers not intending to quit. The investigators will also monitor quality of life, neurocognitive functioning and measure participants' perception and satisfaction of the product

 

3. NCT02124187

Smoking Cessation And Reduction in Depression (SCARID). Caponnetto P., Principal Investigator

Evaluate smoking reduction, smoking abstinence and adverse events in depressed smokers not intending to quit.

 

 

Completed Research Support

 

1. NCT01665066

Pharmacokinetic Profile of Toxic Substances and Nicotine in Electronic Cigarettes (KINECIG)California Department of Health Services.  Caponnetto P., Co-Investigator  

The aim of the present study is to compare serum nicotine levels of different e-Cigarette strength with usual cigarettes

 

2. NCT01188239

A Structured Protocol to Evaluate Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette) Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette). Caponnetto P., Co-Investigator  

The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (E-Cigarette) loaded with low dose nicotine to induce long-term smoking reduction/abstinence in smokers unwilling to quit.

 

3. NCT01194583

Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges. Caponnetto P., Co-Investigator  

The study will monitor smoking reduction/abstinence effects, changes in withdrawal symptoms, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "NO nicotine" cartridges).

 

4. NCT01164072

Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette). Caponnetto P., Co-Investigator .

The study will monitor smoking reduction/abstinence effects, changes in withdrawal symptoms, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges).

 

5. NCT01195597

Smoking Cessation and Reduction With an Electronic Nicotine Delivery Device (ENDD). Caponnetto P., Co-Investigator .

The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (ENDD) to induce long-term smoking reduction/abstinence in smokers unwilling to quit.

 

6. NCT01735487

CogEcig: Cognitive Functioning and Electronic Cigarette. Caponnetto P., Principal-Investigator .

The aim of the present study is to compare cognitive scores (attention, executive function and working memory) of different e-Cigarette strength with usual cigarettes

 

7. NCT02124200

High Cessation Rates in Smokers Using Personal Vaporizers (VAPECIG). Caponnetto P., Co-Investigator .

In this prospective proof-of-concept study we monitored modifications in smoking habits of 50 regular smokers (unwilling to quit) who were asked to switch to a second generation device focusing on smoking reduction and smoking abstinence.

VIEW THE THESES
N.B. the number of theses can affect the loading time of the information